Home-based tDCS for Prevention of Suicidal Ideation
Primary Purpose
Suicidal Ideation
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Home-based transcranial direct current stimulation (tDCS)
Sham home-based transcranial direct current stimulation (tDCS)
Sponsored by
About this trial
This is an interventional other trial for Suicidal Ideation
Eligibility Criteria
Inclusion Criteria:
- For individuals post-hospitalization: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, (DSM-5) admission diagnosis of major depressive disorder or bipolar disorder with suicidal behavior (suicidal behavior at admission will be confirmed using electronic medical record review). All spectrum of suicidal behavior, from suicidal ideation to suicide attempt, are considered suicidal behavior.
- For individuals post-hospitalization: Montgomery-Asberg Depression Rating Scale (MADRS) item 10 score of 0-1 at screening
- For individuals post-hospitalization: Will be in a standard clinical outpatient psychiatric care during the entirety of the study.
Exclusion Criteria:
- Unstable medical condition
- Any history of neurological illness or traumatic brain injury
- Current psychotic symptoms
- Use of illicit drugs other than marijuana in the month previous the hospital admission
- History of borderline or severe personality disorder as determined by clinical judgment, which would significantly interfere with subject's participation in the study
- As participants will use the device at home, participants with a lack of family support at home and/or stable housing will be excluded
- Women who are pregnant or planning to become pregnant during the study
- Since visits will be remote for the study, participants would need to have internet and a device to have a UTHealth-approved web based appointment
Sites / Locations
- University of RochesterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Active home-based transcranial direct current stimulation (tDCS)
Sham home-based transcranial direct current stimulation (tDCS)
Arm Description
The active home-based tDCS delivers a constant current intensity of 2mA on the subject's scalp, with electrodes positioned bilaterally (anodal-left and cathodal-right), on the dorsolateral prefrontal cortex (DLPFC), for 30 minutes.
The sham home-based tDCS looks identical to a typical active home-based tDCS cap but delivers a 30-second ramp-up (0-2 mA) stimulation followed by a 30-second ramp-down (2-0 mA) at the beginning and end of the application.
Outcomes
Primary Outcome Measures
Feasibility of the intervention
Number of completed remotely supervised transcranial direct current stimulation (RS-tDCS) sessions, for both active and sham groups: We expect at least 70% of the subjects to complete at least 5 of recommended 10 RS-tDCS sessions.
Secondary Outcome Measures
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Acceptability of the intervention
Acceptability based on subject's readiness, self-confidence, and satisfaction will be considered if at least 60% of all subject's rate "strongly agree" or "agree" on the acceptability questionnaire item 11: "Overall, I felt that transcranial electrical stimulation treatment benefited me" (the questionnaire is a 5-item Likert scale with the following response options "Strongly agree", "Agree", "Neither agree nor disagree", "Disagree", "Strongly disagree").
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
The level of side effects
The level of side effects will be assessed at the end of each RS-tDCS session on a 0 (not at all) to 10 (highest degree) scale, which includes the following symptoms: 1. Itching; 2. Burning; 3. Headache; 4. Fatigue; 5. Nervousness; 6. Dizziness; 7. Difficulty concentrating. The total score is the sum of the 7 items, varying from 0 to 70. Higher scores indicate higher levels of side effects.
Treatment emergent event
After each RS-tDCS session and clinical assessment, subjects will be asked "Have you had any new symptoms, new medical conditions or been started on new medication/treatment since we last saw you?". This information will help research staff to judge about potential adverse events related to the trial. In addition, changes in treatment will help researchers to account for them in data analysis and the study's results interpretation.
Full Information
NCT ID
NCT05280756
First Posted
March 4, 2022
Last Updated
September 21, 2023
Sponsor
University of Rochester
Collaborators
Brain & Behavior Research Foundation
1. Study Identification
Unique Protocol Identification Number
NCT05280756
Brief Title
Home-based tDCS for Prevention of Suicidal Ideation
Official Title
Home-based Transcranial Direct-current Stimulation (tDCS) for Prevention of Suicidal Ideation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 21, 2023 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
February 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Rochester
Collaborators
Brain & Behavior Research Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Risk for suicide is elevated in the period after discharge from hospital among adults with major affective disorder. The primary objective of this study is to investigate the feasibility of delivering tDCS sessions for high-risk patients for suicide at home in the days following discharge from an emergency department or inpatient unit. This is a single-center, randomized, sham-controlled, double-blind clinical study. We plan to assess up to 80 adult patients for eligibility over 12 months of which 20 will be enrolled and randomized. Clinical assessments will be performed at baseline, post-treatment day 14 (14 days after the first tDCS session), and follow-up day 30 and 60 (30 and 60 days after the first tDCS session, respectively).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Suicidal Ideation
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Active home-based transcranial direct current stimulation (tDCS)
Arm Type
Experimental
Arm Description
The active home-based tDCS delivers a constant current intensity of 2mA on the subject's scalp, with electrodes positioned bilaterally (anodal-left and cathodal-right), on the dorsolateral prefrontal cortex (DLPFC), for 30 minutes.
Arm Title
Sham home-based transcranial direct current stimulation (tDCS)
Arm Type
Sham Comparator
Arm Description
The sham home-based tDCS looks identical to a typical active home-based tDCS cap but delivers a 30-second ramp-up (0-2 mA) stimulation followed by a 30-second ramp-down (2-0 mA) at the beginning and end of the application.
Intervention Type
Device
Intervention Name(s)
Home-based transcranial direct current stimulation (tDCS)
Other Intervention Name(s)
Soterix 1X1 mini-CT Transcranial Direct Current Stimulation (tcDCS) device
Intervention Description
Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
Intervention Type
Device
Intervention Name(s)
Sham home-based transcranial direct current stimulation (tDCS)
Other Intervention Name(s)
Soterix 1X1 mini-CT Transcranial Direct Current Stimulation (tcDCS) device
Intervention Description
Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
Primary Outcome Measure Information:
Title
Feasibility of the intervention
Description
Number of completed remotely supervised transcranial direct current stimulation (RS-tDCS) sessions, for both active and sham groups: We expect at least 70% of the subjects to complete at least 5 of recommended 10 RS-tDCS sessions.
Time Frame
14 days after start of treatment
Secondary Outcome Measure Information:
Title
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Description
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Time Frame
day 14 [+ 7 days] from the first RS-tDCS session
Title
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Description
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Time Frame
day 30 [+ 7 days] from the first RS-tDCS session
Title
Intensity of suicidal ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Description
The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25), with higher scores indicating more severe suicidal ideation.
Time Frame
day 60 [+ 10 days] from the first RS-tDCS session
Title
Acceptability of the intervention
Description
Acceptability based on subject's readiness, self-confidence, and satisfaction will be considered if at least 60% of all subject's rate "strongly agree" or "agree" on the acceptability questionnaire item 11: "Overall, I felt that transcranial electrical stimulation treatment benefited me" (the questionnaire is a 5-item Likert scale with the following response options "Strongly agree", "Agree", "Neither agree nor disagree", "Disagree", "Strongly disagree").
Time Frame
This information will be collected after the final RS-tDCS session (that is, the tenth RS-tDCS session)
Title
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Description
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Time Frame
day 14 [+ 7 days] from the first RS-tDCS session
Title
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Description
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Time Frame
day 30 [+ 7 days] from the first RS-tDCS session
Title
Proportion of patients with no suicidal ideation as assessed by the C-SSRS
Description
Proportion of patients who answered "no" for both questions 1 ("Have you wished you were dead or wished you could go to sleep and not wake up?") and 2 ("Have you actually had any thoughts of killing yourself?") of the C-SSRS
Time Frame
day 60 [+ 10 days] from the first RS-tDCS session
Title
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
Description
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Time Frame
day 14 [+ 7 days] from the first RS-tDCS session
Title
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
Description
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Time Frame
day 30 [+ 7 days] from the first RS-tDCS session
Title
Intensity of rumination as assessed by the Ruminative Responses Scale (RRS)
Description
The RRS encompasses 22 items. Each item is rated on a 4-point Likert scale: 1, almost never; 2, sometimes; 3, often; 4, almost always. The score on this scale is obtained by simply summing the scores on the 22 items.
Time Frame
day 60 [+ 10 days] from the first RS-tDCS session
Title
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
Description
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Time Frame
day 14 [+ 7 days] from the first RS-tDCS session
Title
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
Description
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Time Frame
day 30 [+ 7 days] from the first RS-tDCS session
Title
Symptoms associated with suicidal ideation as assessed by the Concise Associated Symptoms Tracking (CAST) scale
Description
The 16 items of the CAST Scale assess symptoms across five domains: anxiety (three items, subscore range 3-15), irritability (five items, subscore range 5-25), mania (four items, subscore range 4-20), insomnia (two items, subscore range 2-10), and panic (two items, subscore range 2-10). The total CAST score ranges from 16 to 80. Each item is rated on a 5-point Likert scale: 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree; or 5, strongly agree, with higher scores indicating more severe symptoms.
Time Frame
day 60 [+ 10 days] from the first RS-tDCS session
Title
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
Description
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
Time Frame
day 14 [+ 7 days] from the first RS-tDCS session
Title
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
Description
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
Time Frame
day 30 [+ 7 days] from the first RS-tDCS session
Title
Depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
Description
MADRS is a 10-item questionnaire that includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A higher MADRS score indicates more severe depression.
Time Frame
day 60 [+ 10 days] from the first RS-tDCS session
Title
The level of side effects
Description
The level of side effects will be assessed at the end of each RS-tDCS session on a 0 (not at all) to 10 (highest degree) scale, which includes the following symptoms: 1. Itching; 2. Burning; 3. Headache; 4. Fatigue; 5. Nervousness; 6. Dizziness; 7. Difficulty concentrating. The total score is the sum of the 7 items, varying from 0 to 70. Higher scores indicate higher levels of side effects.
Time Frame
The level of side effects will be assessed at the end of each RS-tDCS session
Title
Treatment emergent event
Description
After each RS-tDCS session and clinical assessment, subjects will be asked "Have you had any new symptoms, new medical conditions or been started on new medication/treatment since we last saw you?". This information will help research staff to judge about potential adverse events related to the trial. In addition, changes in treatment will help researchers to account for them in data analysis and the study's results interpretation.
Time Frame
The level of side effects will be assessed at the end of each RS-tDCS session and at days 14 [+ 7 days], 30 [+ 7 days], and 60 [+ 10 days] from the first RS-tDCS session
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age between 18 and 65 years
diagnosis of mood or bipolar disorder registered in the electronic hospital medical record
history of suicidal ideation and/or suicide behavior at the time of admission registered in the electronic hospital medical record
absent of suicidal ideation at the time of enrollment (defined as questions 1 and 2 of the C-SSRS answered "no")
ability and willingness to provide information and permission to contact at least one person in the case of a need to contact them to promote subject safety or inability to reach the subject for follow-up
a living situation with access to a private space suitable for the administration of the RS-tDCS sessions in the next three weeks
living in Monroe County region, as this is the area covered by the Mobile Crisis Team, a URMC psychiatric emergency team serving anyone within Monroe County
device or computer with internet access for a URMC-approved remote RS-tDCS supervision
ability to manage proper use of the device in a practice session
Exclusion Criteria:
acute psychiatric instability or substance abuse (e.g., psychotic symptoms, alcohol misuse, use of any illicit drugs in the previous three months)
unstable medical condition with reduction of functional capacity
history of epilepsy or seizures in the last year
history of neurodegenerative diseases registered in the electronic hospital medical record
presence of or implanted any ferromagnetic metal in the head or the neck
pregnant or breastfeeding or willingness to become pregnant in the next month
history of head trauma (e.g., head injury, brain injury) or neurosurgery
history of skin disorder or sensitive skin area near stimulation locations
the presence of pacemaker
current treatment with electroconvulsive therapy or transcranial magnetic stimulation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandre Paim Diaz, MD, PhD
Phone
585-273-2047
Email
Alexandre_PaimDiaz@URMC.Rochester.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yeates Conwell, MD
Organizational Affiliation
University of Rochester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandre Paim Diaz, MD, PhD
Phone
585-273-2047
Email
Alexandre_PaimDiaz@URMC.Rochester.edu
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
We are investigating options for making unidentifiable research data from individual participants available for public sources such as Harvard Dataverse.
Learn more about this trial
Home-based tDCS for Prevention of Suicidal Ideation
We'll reach out to this number within 24 hrs